At Idenix, partnerships have played an important role in our development as a company, and we remain committed to building collaborations that can expand or advance our pipeline for the treatment of life-threatening diseases.
We believe we have core competencies in nucleoside/nucleotide chemistry, prodrug technologies, and development of infectious disease therapeutics. We have historically been focused on discovering and developing antivirals, most recently striving to cure HCV. We are now actively exploring how to apply our areas of expertise to potential new indications. Specifically, we are exploring and open to partnerships on antivirals, antibacterials and oncology therapeutics.
If you are interested in pursuing a partnership opportunity with Idenix and/or have a compelling technology you think would benefit our pipeline, we welcome you to contact us at firstname.lastname@example.org.
In January 2013, Idenix announced a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. for the clinical development of all-oral direct-acting antiviral HCV combination therapies. The collaboration will evaluate combinations including samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, Olyso™ (simeprevir), a once-daily protease inhibitor jointly developed by Janssen and Medivir AB, and TMC647055, a once-daily non-nucleoside polymerase inhibitor, boosted with low-dose ritonavir, being developed by Janssen.